In a report released on June 16, Thomas Smith from Leerink Partners maintained a Buy rating on Disc Medicine (IRON – Research Report), with a price target of $85.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thomas Smith has given his Buy rating due to a combination of factors that highlight Disc Medicine’s promising developments in their hematology-focused pipeline. The company is on track to submit a New Drug Application for bitopertin, an oral GlyT1 inhibitor, which is expected to leverage an accelerated approval pathway. This progress is supported by promising initial data from the HELIOS long-term extension study, showing sustained reductions in PPIX, improvements in liver function, and a clean safety profile.
Additionally, Disc Medicine’s ongoing trials, such as the Phase 1b MF anemia trial and the Phase 2 RALLY-MF trial, have shown encouraging results with enhanced biomarker responses. The inclusion of patients receiving momelotinib/pacritinib in the RALLY-MF trial is seen as a positive step that may accelerate enrollment and enhance real-world applicability. Furthermore, updated data on DISC-3405, including its ability to inhibit iron absorption, adds to the positive outlook for Disc Medicine. These developments collectively contribute to Thomas Smith’s positive outlook and Buy rating for Disc Medicine’s stock.
Smith covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Sagimet Biosciences, Inc. Class A, and Viking Therapeutics. According to TipRanks, Smith has an average return of 32.0% and a 46.50% success rate on recommended stocks.
In another report released on June 17, BMO Capital also reiterated a Buy rating on the stock with a $120.00 price target.